Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model.

Molecular cancer therapeutics - 1 Sept 2021

Zou Minjing, BinEssa Huda A, Al-Malki Yousif H, Al-Yahya Suhad, Al-Alwan Monther, Al-Jammaz Ibrahim, Khabar Khalid S A, Almohanna Falah, Assiri Abdullah M, Meyer Brian F, Alzahrani Ali S, Al-Mohanna Futwan A, Shi Yufei

Abstract excerpt

BRAFV600E mutation is the most frequent genetic alteration in papillary thyroid cancer (PTC). β-Catenin (Ctnnb1) is a key downstream component of canonical Wnt signaling pathway and is frequently overexpressed in PTC. BRAF V600E-driven tumors have been speculated to rely on Wnt/β-catenin signaling to sustain its growth, although many details remain to be elucidated. In this study, we investigated the role of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Wnt Signaling Pathway

Source

Identifiers

PMID: 34224366
DOI: 10.1158/1535-7163.MCT-21-0037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model.PMID 34224366Read ↗

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.Semantic proximity Read ↗

Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.Semantic proximity Read ↗

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.Semantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.Semantic proximity Read ↗

Lessons from Mouse Models of Thyroid CancerSemantic proximity Read ↗

Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAF V600E ‐associated thyroid carcinomaSemantic proximity Read ↗

ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activationSemantic proximity Read ↗

Acceleration of BRAFV600E-induced thyroid carcinogenesis by TGFβ signal deficiency in mice.Semantic proximity Read ↗

Mouse models of thyroid cancer: A 2015 update.Semantic proximity Read ↗

Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.